AOD 9604
The AOD-9604 research library

AOD 9604 peptide,
explained in depth.

A complete research library on AOD-9604 — the modified growth hormone fragment developed as an oral anti-obesity drug. Real clinical data, dosing protocols, side effect profiles, and head-to-head comparisons with semaglutide and tirzepatide.

Read the dosage guide → How it works
PeptidehGH 176–191
Molecular weight1815.1 Da
Half-life~38 min
FDA statusInvestigational
Start here

What is AOD 9604?

AOD-9604 (Anti-Obesity Drug 9604) is a modified 15-amino-acid fragment of the C-terminus of human growth hormone, engineered to isolate the fat-mobilizing activity of hGH while avoiding its effects on IGF-1, insulin resistance, and tissue growth. It was developed at Monash University and advanced into human trials by Metabolic Pharmaceuticals as an oral anti-obesity therapy.

aod 9604 dosage aod 9604 side effects aod 9604 before and after aod 9604 weight loss aod 9604 benefits aod 9604 vs semaglutide aod 9604 vs tirzepatide aod 9604 cost aod peptide aod 9604 oral
Browse the guide

Every major AOD 9604 topic, covered in depth.

Dosage protocols, side effect data, clinical trial results, comparisons with GLP-1 drugs, and oral versus injectable bioavailability — all in one place.

01 / 10

AOD 9604 dosage

Subcutaneous and oral dosing protocols, vial math for 2mg/5mg/10mg, reconstitution, timing, and cycle structure.

Read page → 02 / 10

AOD 9604 benefits

Mechanism of action, fat-mobilizing activity, preclinical fat-loss data, and what AOD 9604 was actually engineered to do.

Read page → 03 / 10

AOD 9604 side effects

Documented side effects from Phase II trials, injection site reactions, and why the safety profile is cleaner than hGH.

Read page → 04 / 10

AOD 9604 weight loss

What the clinical weight loss data actually shows, user-reported results, and the rodent-to-human translation gap.

Read page → 05 / 10

AOD 9604 before and after

Realistic 4/8/12-week results timelines drawn from clinical data and user reports.

Read page → 06 / 10

AOD 9604 results

Pharmacokinetics, onset timeline, peak effects, and what the results curve actually looks like.

Read page → 07 / 10

AOD 9604 vs semaglutide

Mechanism, efficacy, side effects, cost, and regulatory status — the honest head-to-head.

Read page → 08 / 10

AOD 9604 vs tirzepatide

Head-to-head comparison with the most effective weight loss drug currently on the market.

Read page → 09 / 10

AOD 9604 cost and availability

Pricing, prescription status, the FDA bulks list history, and the current regulatory reality.

Read page → 10 / 10

Oral AOD 9604: troches, capsules and bioavailability

Troches, capsules, lozenges, nasal sprays — and whether oral AOD 9604 actually works.

Read page →
The short version

AOD 9604 in five facts

FactDetail
OriginSynthetic analog of amino acids 176–191 of human growth hormone, plus an N-terminal tyrosine for stability.
DeveloperMetabolic Pharmaceuticals Ltd. (Australia), licensed from Monash University.
MechanismStimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) without binding hGH receptors in growth or insulin pathways.
Clinical statusCompleted Phase IIb trials for obesity in 2007; did not meet primary endpoint for clinically significant weight loss versus placebo.
Current statusNot FDA-approved. Previously compounded in the U.S. under §503A; removed from the FDA bulks list. Classified as a prohibited substance by WADA.